Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00255125
Other study ID # CLIN-006-05S
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date September 2005
Est. completion date October 2009

Study information

Verified date June 2019
Source VA Office of Research and Development
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized study evaluating the effectiveness and direct effect a commercial soy supplement has on prostate cancer and normal prostate tissue. Patient will be randomized it either receive placebo or a commercial soy supplement for 2-4 weeks prior to the planned surgery for treatment of their prostate cancer. Patient's blood and prostate tissue will be evaluated to determine the effects of the soy supplement on the prostate tissue.


Description:

This is a randomized study evaluating the effectiveness and direct effect a commercial soy supplement has on prostate cancer and normal prostate tissue. Patients will be randomized to either receive placebo or a commercial soy supplement for 2-4 weeks prior to the planned surgery for treatment of their prostate cancer. The specific objectives are:

1. To assess the effect of soy supplementation on endogenous hormone production levels and serum prostate specific antigens.

2. To assess the impact of soy supplementation on estrogen receptor expression(ER).

3. To determine the impact of soy isoflavones on cell cycle regulation and associated gene expression.


Other known NCT identifiers
  • NCT00285480

Recruitment information / eligibility

Status Completed
Enrollment 86
Est. completion date October 2009
Est. primary completion date April 2009
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically proven prostate cancer.

- Surgical candidate for prostatectomy.

- During study period, must agree not to take new supplements.

- No concurrent chemotherapy, radiation or hormonal therapy.

- No history of prior allergy to soy based products.

- Must not have been taking soy supplements or soy isoflavones within 90 days prior to study enrollment.

- Must be able to safely be on study supplements for period of at least two weeks prior to scheduled prostatectomy.

- Must give written and informed consent in accordance with institutional and federal guidelines.

Exclusion Criteria:

During study period, must agree not to take new supplements.

- No concurrent chemotherapy, radiation or hormonal therapy.

- No history of prior allergy to soy based products.

- Must not have been taking soy supplements or soy isoflavones within 90 days prior to study enrollment.

- Must be able to safely be on study supplements for period of at least two weeks prior to scheduled

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Soy Supplement
Soy protein supplement will be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).
Placebo
Placebo will consist of a capsule without the soy protein added to be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).

Locations

Country Name City State
United States VA Medical Center, Kansas City MO Kansas City Missouri

Sponsors (1)

Lead Sponsor Collaborator
VA Office of Research and Development

Country where clinical trial is conducted

United States, 

References & Publications (1)

Hamilton-Reeves JM, Banerjee S, Banerjee SK, Holzbeierlein JM, Thrasher JB, Kambhampati S, Keighley J, Van Veldhuizen P. Short-term soy isoflavone intervention in patients with localized prostate cancer: a randomized, double-blind, placebo-controlled tria — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Effect of Soy Isoflavones on Serum Testosterone Levels. Total testosterone (ng/ml) serum levels were measured at the time of enrollment(baseline), after two weeks on soy supplement(time point 1), and just prior to prostatectomy (time point 2). All patients must have completed at least two week of soy supplement or placebo and time point 3 varied depending on date of planned prostatectomy. Results were analyzed and are reported at the two week time period, comparing between patients receiving soy supplement or placebo. Two weeks
Secondary Effect of Soy Isoflavones on Estrogen Receptor Status Samples of the prostate cancer tissue (paraffin embedded) were sectioned and placed on a glass slide. Using immunohistochemistry and an estrogen receptor antibody, sections were stained and assess to determine the extent of estrogen receptor expression. Patients in the soy supplement arm's samples results were compared to placebo arm results. Two weeks
Secondary Molecular Effects of Soy Supplementation Compared to Placebo. Using a tissue microarray targeting the cell cycle, selected fresh prostate cancer samples were evaluated in patients in the soy supplement arm compared to the placebo arm. One year
See also
  Status Clinical Trial Phase
Recruiting NCT06315595 - Improvements in Dynamic Contrast-Enhanced MR Angiography and Perfusion
Withdrawn NCT05191017 - Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC Phase 1/Phase 2
Terminated NCT02809690 - 18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer Phase 1
Completed NCT06020287 - The Robot-Assisted Laparoscopic Radical Prostatectomy Combined Anterior and Posterior Approach
Recruiting NCT03572946 - Targeted Biopsy or Standard Biopsy for Clinical Significant Prostate Cancer Detection N/A
Active, not recruiting NCT03344757 - Health Gatherings - For Your Health After Cancer N/A
Recruiting NCT05137561 - Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed TRUS Guided Prostate Biopsy N/A
Recruiting NCT04792138 - Learning MRI and Histology Image Mappings for Cancer Diagnosis and Prognosis.
Completed NCT03702439 - Prostate Cancer Screening Trial Using Imaging
Completed NCT04852224 - Strength, Aging, and Memory in Prostate Cancer
Completed NCT01240551 - F-18 Sodium Fluoride in Prostate Cancer Phase 2
Not yet recruiting NCT06430411 - Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study
Recruiting NCT02436122 - Impact of Preoperative HbA1c Levels on Pathologic Features and Oncological Outcomes in the Patients With Prostate Cancer N/A
Active, not recruiting NCT03493945 - Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) Phase 1/Phase 2
Completed NCT04376008 - A Prospective Study Of Free-Hand Transperineal Image Fusion Targeted Biopsies Under Local Anesthesia N/A
Recruiting NCT05252390 - NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06292897 - Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression
Recruiting NCT03819751 - MRI-targeted Biopsy of the Prostate: Software Versus Visual Registration in the Accuracy of Prostate Cancer Detection N/A
Not yet recruiting NCT05460312 - Protein Kinase A in Prostate Cancer Tissue.
Completed NCT00005916 - PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer Phase 2